6 completed, 1 recruiting, 1 terminated, 1 unknown. 9 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 6, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Cytomegalovirus Infection: new trials by email Literature Review of Cytomegalovirus Infection trials Research Report on Cytomegalovirus Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections Letermovir, Valganciclovir, Letermovir placebo - Cytomegalovirus Infection | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 80 | 2024-08-14 | 2026-01-02 |
| A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045) Letermovir - Cytomegalovirus Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 120 | 2023-03-24 | 2025-03-25 |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age mRNA-1647, Placebo - Cytomegalovirus Infection | Phase 3 | Terminated | ModernaTX, Inc. | 7454 | 2021-10-26 | 2025-12-15 |
| MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042) Letermovir tablet, Letermovir IV - Cytomegalovirus Infection, Cytomegalovirus Disease | Phase 3 | Completed | Merck Sharp & Dohme LLC | 22 | 2019-12-27 | 2024-08-21 |
| Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040) Letermovir, Placebo - Cytomegalovirus Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 220 | 2019-06-21 | 2024-08-22 |
| Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection HCMV-specific hyperimmune globulin (Cytotect®), Isotonic solution of sodium chloride (placebo) - Cytomegalovirus Infection | Phase 2 / Phase 3 | Completed | Fondazione IRCCS Policlinico San Matteo di Pavia | 124 | 2009-06-01 | 2011-12-08 |
| Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy Pre-emptive strategy with valganciclovir plus everolimus, Prophylaxis with valganciclovir plus mycophenolate, Prophylaxis with valganciclovir plus everolimus - Heart Transplantation, Cardiac Allograft Vasculopathy | Phase 3 | Unknown | University of Bologna | 100 | 2009-04-01 | 2009-08-27 |
| Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study Adoptive Cellular Therapy, Best available antiviral drug therapy - Cytomegalovirus Infection | Phase 3 | Completed | Cell Medica Ltd | 89 | 2008-07-01 | 2018-01-25 |
| Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections Placebo, Valganciclovir - Cytomegalovirus Infection | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 109 | 2008-06-01 | 2015-08-26 |
Cytomegalovirus Infections (9) · DNA Virus Infections (1) · Virus Diseases (1)
Herpesviridae Infections (9) · Infections (9) · DNA Virus Infections (8) · Virus Diseases (8)
letermovir (4) · Valganciclovir (3) · Everolimus (1) · Immunotherapy, Adoptive (1) · Mycophenolic Acid (1) · cytomegalovirus-specific hyperimmune globulin (1) · mRNA-1647 cytomegalovirus vaccine (1)
Merck Sharp & Dohme LLC (3) · Assistance Publique - Hôpitaux de Paris (1) · Cell Medica Ltd (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · ModernaTX, Inc. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of Bologna (1)
Italy (4) · United Kingdom (4) · France (3) · Japan (3) · United States (3) · Germany (2) · Australia (1) · Belgium (1) · Canada (1) · China (1) · Estonia (1) · Finland (1) · Israel (1) · Spain (1)
Karl S Peggs (1) · Maria Grazia Revello, MD (1)
PMID 24693891, PMID 25738669, PMID 36102707, PMID 36464218, PMID 37899366, PMID 38142695, PMID 38190492, PMID 38615067, PMID 38700045, PMID 39807668
2023 (2), 2018 (1)